The Michael J. Fox Foundation for Parkinson's Research
  Research
  News & Events
  Funding Programs
  About

PD Online Research

Alzheimer Research Forum
  Current Papers
  ARF Recommends
  Research News
PDGene - Gene overview of all published PD-association studies for GBA
Back Search Methods Disclaimer Credits
 Gene: GBA  (GCB; GBA1; GLUC)  Entrez Gene    View on AlzGene
 Protein: glucocerebrosidase  (glucocerebrosidase (alt.); lysosomal glucocerebrosidase; D-glucosyl-N-acylsphingosine glucohydrolase)  ProteinLink
 Chromosome: 1   (View: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  X  Y  MT)
 Status: Updated 17 December 2012
Meta-Analysis
1. Case-Control Studies (by ethnic group)
      PD Cases Normal Controls  
Study Population Source # Polys # Subjects
(% women)
DX Onset Age
(range)
Age
(range)
# Subjects
(% women)
Age
(range)
Result
 Caucasian
Aharon-Peretz, 2004
Israel CL  1  (detail)  99
(44%)
C--1543
(-)
-Trend
Bras, 2007
Overlaps with
Sidransky, 2009 (Portugal)
CL  2  (detail)  230
(-)
C--430
(-)
-Positive
Clark, 2005
Overlaps with
Clark, 2007
CL  1  (detail)  160
(38%)
C59 + 12.4
(-)
66.5 + 10.5
(-)
92
(41%)
69.6 + 9.6
(-)
n.a.
Clark, 2007
USA CL  2  (detail)  278
(37%)
C-65.6 + 11.3
(-)
179
(44%)
64.9 + 11.3
(-)
Positive
De Marco, 2008
Italy CL  1  (detail)  395
(38%)
C60.3 + 10.2
(-)
66.4 + 9.1
(-)
483
(63%)
56.9 + 17.3
(-)
Positive
Do, 2011
USA (23andMe-GWAS) CL  1  (detail)  3426
(40%)
M57.4 + 10.7
(-)
64.3 + 10.6
(-)
29624
(42%)
48.2 + 16
(-)
Positive
Emelyanov, 2011
Russia CL  1  (detail)  330
(-)
C-63.8 + 9.8
(-)
240
(-)
67.7 + 8.8
(-)
Positive
Fung, 2006
Overlaps with
Simon-Sanchez, 2009 (USA)
CL  2  (detail)  267
(-)
C--270
(-)
68
(55-88)
n.a.
Gan-Or, 2008
Israel CL  1  (detail)  420
(38%)
C59.4 + 11.3
(21-94)
67.9 + 10.2
(41-96)
4138
(-)
-Positive
Lesage, 2010
France CL  2  (detail)  1130
(-)
C--391
(-)
-Positive
Lwin, 2004
USA CL  2  (detail)  56
(-)
N-76
(54-99)
44
(-)
70
(-)
Trend
Mata, 2008
Overlaps with
Sidransky, 2009 (USA)
CL  1  (detail)  721
(25%)
C58.2 + 12
(-)
67.1 + 11
(-)
554
(64%)
65.3 + 12.5
(-)
n.a.
Moraitou, 2011
Greece CL  1  (detail)  205
(52%)
C-64.2
(37-88)
206
(-)
66.8 + 114
(40-95)
Positive
Neumann, 2009
UK CL  1  (detail)  790
(22%)
M58.7 + 12.3
(-)
-257
(-)
53
(-)
Positive
Nichols, 2008
Overlaps with
Pankratz, 2008 (USA-PROGENI)
CL  2  (detail)  450
(-)
C--359
(56%)
70.3
(55-92)
Positive
Pankratz, 2008
USA (PROGENI, GenePD) CL  3  (detail)  857
(41%)
C61.9 + 10.8
(-)
-867
(60%)
54.8 + 13.1
(-)
Negative
Sato, 2005
Canada CL  1  (detail)  88
(41%)
C41.2 + 12.9
(14-72)
58.4 + 13.7
(-)
122
(59%)
65 + 8.6
(47-80)
Positive
Sidransky, 2009
Overlaps with
Toft, 2006 (Norway)
CL  1  (detail)  311
(40%)
C--473
(44%)
64.1
(-)
n.a.
Sidransky, 2009
Overlaps with
Sato, 2005 (Canada)
CL  1  (detail)  88
(42%)
C-55
(-)
96
(72%)
69.6
(-)
n.a.
Sidransky, 2009
Overlaps with
De Marco, 2008 (Italy)
CL  1  (detail)  395
(38%)
C-66.5
(-)
483
(63%)
56.9
(-)
n.a.
Sidransky, 2009
Portugal CL  2  (detail)  231
(52%)
C-65.3
(-)
482
(-)
65.5
(-)
n.a.
Sidransky, 2009
Germany (Tuebingen) CL  1  (detail)  377
(41%)
C-64.8
(-)
325
(41%)
58.3
(-)
n.a.
Sidransky, 2009
Germany (Rostock) CL  2  (detail)  298
(36%)
C-64.3
(-)
212
(50%)
74.5
(-)
Trend
Sidransky, 2009
France CL  1  (detail)  297
(38%)
C-57.8
(-)
251
(43%)
57.8
(-)
Positive
Simon-Sanchez, 2009
USA, Germany (GWAS) CL,PO  2  (detail)  1745
(45%)
C55.8
(7-98)
-4047
(50%)
-Negative
Simon-Sanchez, 2009
USA (NINDS-GWAS) CL  1  (detail)  931
(40%)
C--790
(58%)
-Negative
Sutherland, 2009
Australia CL  2  (detail)  331
(51%)
C60.1 + 10.6
(-)
70.3 + 8.7
(-)
296
(51%)
70.5 + 8.9
(-)
Negative
Toft, 2006
Norway CL  1  (detail)  311
(40%)
C59 + 10.9
(31-88)
-474
(-)
60.5
(-)
Negative
 Asian
Hu, 2010
China CL  1  (detail)  328
(46%)
C52.6 + 11.8
(-)
-300
(-)
-Trend
Sidransky, 2009
Taiwan CL  2  (detail)  559
(46%)
C-69.1
(-)
377
(47%)
60.5
(-)
Negative
Sidransky, 2009
Singapore CL  1  (detail)  329
(48%)
C-70.3
(-)
201
(51%)
64.2
(-)
Negative
Sidransky, 2009
Japan CL  2  (detail)  534
(47%)
C-65.3
(-)
546
(46%)
44.8
(-)
Negative
Sun, 2010
China CL  1  (detail)  402
(40%)
C54.7 + 12.1
(8-79)
-413
(-)
-n.a.
 Other/Mixed
Eblan, 2006
Venezuela CL  1  (detail)  33
(-)
C36
(24-50)
36
(-)
31
(-)
-Positive
Lesage, 2011
Algeria, Morocco, Tunisia, Libya CL  3  (detail)  194
(48%)
C50.9 + 12.9
(12-78)
58.8 + 13.3
(14-83)
177
(61%)
49.5 + 14.5
(19-84)
Positive
Nishioka, 2009
Tunisia CL  2  (detail)  240
(52%)
C57.1 + 13
(-)
-372
(49%)
58.3 + 11
(-)
Negative
Santos, 2010
Brazil CL  1  (detail)  110
(33%)
C41.2 + 8
(-)
52.6 + 10.8
(-)
155
(47%)
62.7 + 9.4
(-)
Positive
Sidransky, 2009
USA (Seattle) CL  2  (detail)  811
(25%)
C-66.9
(-)
518
(63%)
65.2
(-)
Positive
Sidransky, 2009
Overlaps with
Gan-Or, 2008 (Israel)
CL  1  (detail)  420
(38%)
C-68
(-)
321
(50%)
65.3
(-)
n.a.
Sidransky, 2009
USA (NHGRI) CL  2  (detail)  539
(31%)
C-73.5
(-)
209
(52%)
67.6
(-)
Trend
Sidransky, 2009
Overlaps with
Clark, 2007 (USA)
CL  2  (detail)  275
(38%)
C-65.6
(-)
140
(48%)
62.8
(-)
n.a.
Sidransky, 2009
Brazil CL  1  (detail)  65
(35%)
C-54.1
(-)
264
(36%)
54.4
(-)
n.a.
Contact us if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.
2. Family-Based Studies (by ethnic group)
      Affecteds Unaffecteds  
Study Population # Polys # Families # Subjects
(% women)
DX Onset Age
(range)
Age
(range)
# Subjects
(% women)
Age
(range)
Result
 Caucasian
Lesage, 2010
Overlaps with
Lesage, 2010 (CC)
 2  (detail)  21-C--50
(-)
-Positive
Contact us if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.
Source:  Source of case population -> “CL” (clinic-based), “PO” (population-based), or “CO” (community-based).
# Polys:  Number of polymorphisms tested per gene and per sample.
Onset Age and Age:  Mean or median age at onset or examination, respectively.
DX:  Criteria used to determine PD diagnosis ->  "C" (clinical PD diagnosis), "N" (neuropathological PD diagnosis), "M" (mixed, i.e. PD sample contains both clinical and neuropathological cases), "U" (unknown).
Result:  Overall conclusion reached by authors of the original publication (“positive” usually indicates significant (P<0.05) association in at least one of the performed analyses, and “negative” indicates no evidence for significant association, while “trend” indicates results in between).
(-) :  Either no data provided or in case of overlap, data included in original study.
Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
PDGene Recent Updates
PDGene Top Results
PDGene Stats
Studies: 881
Genes: 915
Polymorphisms: 3446
Meta-analyses: 889
PDGene Links
GEO-PD Meeting 2012
PDmutDB
Curated by the VIB Department of Molecular Genetics of the University of Antwerp
Parkinson's disease Mutation Database
Curated by Parkinson's Institute from Leiden University Medical Center
Mutation Database for Parkinson's Disease
Curated by the Institute for Infocomm Research in Singapore
Michael J. Fox Foundation
The PDGene database is supported by a grant from The Michael J. Fox Foundation in partnership with the Alzheimer Research Forum.
PD Online Research
Alzheimer Research Forum
ALSGene
AlzGene
MSGene
PDGene
SZGene
An up-to-date collection of all published genetic association studies.
Copyright © 2014 Biomedical Research Forum LLC Disclaimer Copyright